Biotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts

Zachary Brennan

Senior Editor

Biopharma companies with pending applications at the FDA have “already encountered regulatory difficulties that we believe are the consequences of the FDA’s loss of experienced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Makary wants to replace animal testing with organoids. It may take a while

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Pharma tariffs: Here’s what a potential rollout could look like

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer

Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool

Biotech CEOs to Cas­sidy: We're al­ready see­ing the ef­fects of FDA's staff cuts

Zachary Brennan

Senior Editor

Sign up to read this article for free.

more like this

Makary wants to re­place an­i­mal test­ing with organoids. It may take a while

Mar­ket tur­moil is tank­ing biotech M&A and IPOs. Here's the play­book star­tups will use to sur­vive

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

Phar­ma tar­iffs: Here’s what a po­ten­tial roll­out could look like

Bris­tol My­er­s' im­munother­a­py com­bo nets ap­provals in col­orec­tal and liv­er can­cer

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Biotech CEOs to Cassidy: We're already seeing the effects of FDA's staff cuts

Makary wants to replace animal testing with organoids. It may take a while

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Recruiters say some biopharmas pause hiring as they struggle to make sense of ongoing uncertainty

Pharma tariffs: Here’s what a potential rollout could look like

Bristol Myers' immunotherapy combo nets approvals in colorectal and liver cancer

Tome Bio founders wrangle ‘jumping genes’ to create new programmable gene insertion tool